NCT02676349 2026-03-27
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Phase 2 Completed
Clinical Trials
15 trialsNCT04016142 2026-03-18
ACCRAPAN
Centre Oscar Lambret
Phase 2 Terminated
NCT07450183 2026-03-04
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
Henry Ford Health System
Phase 2 Not yet recruiting
NCT07423611 2026-02-20
RACE
Fudan University
Phase 2 Not yet recruiting
NCT02662504 2026-02-05
MesoPDT
University Hospital, Lille
Phase 2 Completed
NCT04567420 2025-10-16
DARE
Criterium, Inc.
Phase 2 Recruiting
NCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT04747145 2025-08-21
Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT07089199 2025-07-28
TitAN
Qilu Hospital of Shandong University
Phase 2 Not yet recruiting
NCT07067268 2025-07-16
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
Fudan University
Phase 2 Recruiting
NCT00354393 2025-07-15
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
The Cleveland Clinic
Phase 2 Completed
NCT06914440 2025-07-15
Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer
Xijing Hospital
Phase 2 Recruiting
NCT06953882 2025-07-14
SELECT
Yale University
Phase 2 Recruiting
NCT06646445 2025-06-13
PREMICES
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Not yet recruiting
NCT06942663 2025-04-24
JAGC1
Nizhny Novgorod Regional Clinical Oncology Center
Phase 2 Not yet recruiting